Fellow
Dr. Ervin SHU
CEO of biorocks
Dr. Shu, a Tsinghua University postdoc with a Ph.D. in Biomedical Engineering and an MPhil in Biology from HKUST, has 16 years of bioscience R&D, management, and investment experience. As the CEO of Biorocks, Dr. Shu leads his second startup, an innovative firm in assisted reproduction tech, focusing on high-throughput automated equipment production and development. The team features Ph.D. graduates from prestigious universities like Harvard, Tsinghua, and HKUST, and industry experts skilled in microfluidics, medical device production, registration, and sales. Biorocks has secured five investment rounds from top Chinese investors.
Company Description
Biorocks is committed to resolving challenges in IVF procedures by championing the automation of in vitro fertilization operations. Using microfluidic chip technology, we have a three-fold approach to enhancing IVF success rates:
Standardization: We aim to standardize embryo and oocyte operations, eradicating human error and ensuring consistent results, free from fluctuations.
Streamlined Automation: Our technology not only simplifies the traditionally complex vitrification process but also makes it more efficient.
Reduced Dependence: With our advancements, the heavy reliance on embryologists and intricate manual methods becomes a thing of the past.
Together, these strategies bolster our mission to elevate the success rate of IVF.